Personalis Expands Medicare Coverage for NeXT Personal Test to Include Immunotherapy Monitoring
PSNL sits 66% above its 52-week low of $3.84 on elevated volume (3.2× avg).
Summary
Personalis, Inc. announced expanded Medicare coverage for its NeXT Personal test, now including immunotherapy monitoring for late-stage solid tumors, which is expected to drive revenue growth.
Key Events · Product Development and Regulatory · PSNL
-
Expanded Medicare Coverage
The Centers for Medicare & Medicaid Services (CMS) expanded coverage for the ultrasensitive NeXT Personal® test to include immunotherapy monitoring for patients with late-stage solid tumors.
Analysis · PSNL · Industrial Applications And Services
This expanded Medicare coverage for the NeXT Personal test to include immunotherapy monitoring for late-stage solid tumors is a significant positive development. It broadens the market for a key diagnostic product, potentially boosting revenue for a company that recently reported a 25% year-over-year revenue decline and increased net losses. This helps to improve the company's financial runway and reduces reliance on dilutive capital raises.
At the time of this filing, PSNL was trading at $6.39 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $669.2M. The 52-week trading range was $3.84 to $11.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.